Singapore, Oct. 7 -- Docquity, the Singapore-based clinical AI platform for more than 75% of verified doctors across Asia, has announced its scale up plan into Japan through a deepened strategic partnership with exMedio Inc., operator of the specialist physician communities Hematology Pro and Hipokura.

The move advances Docquity's goal of building Asian Healthcare Intelligence, grounded in Clinical Intent: what doctors across Asia need answered at the point of care.

Docquity Holdings and Docquity Japan G.K. have signed a Memorandum of Understanding (MoU) with exMedio that places Ask Dx, Docquity's clinical AI assistant, at the core of the partnership.

The MoU builds on a collaboration that began in 2025, when Docquity first offered Ask...